Trial Profile

A Phase 1b Multi-center Clinical Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Selumetinib (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

30 Oct 2024 Timeframe for primary endpoints 'Number of Participants Who Experienced Adverse Event (AE)' and 'Number of Participants Discontinuing Study Treatment Due to an Adverse Event' has been changed.
08 Jul 2022 Status changed from active, no longer recruiting to completed.
27 Jan 2022 Planned End Date changed from 13 Jun 2022 to 22 Jun 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com